Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-05-19
2000-01-18
Burke, Julie
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
5303873, 53038822, 4241431, 435 721, 435 696, 435 697, 435328, 435334, A61K 39395, C12N 520, C07K 1628
Patent
active
060155558
ABSTRACT:
The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor and the antibody is a chimera between the variable region from one animal source and the constant region from a different animal source. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.
REFERENCES:
patent: 4292425 (1981-09-01), Buckler et al.
patent: 4434156 (1984-02-01), Trowbridge
patent: 4444744 (1984-04-01), Goldenberg
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4569789 (1986-02-01), Blattler et al.
patent: 4626507 (1986-12-01), Trowbridge et al.
patent: 4631190 (1986-12-01), Shen et al.
patent: 4801575 (1989-01-01), Pardridge
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 4992255 (1991-02-01), Pardridge
patent: 5004697 (1991-04-01), Pardridge
patent: 5028697 (1991-07-01), Johnson et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5130129 (1992-07-01), Pardridge
patent: 5132405 (1992-07-01), Huston et al.
patent: 5141736 (1992-08-01), Iwasa et al.
patent: 5154924 (1992-10-01), Friden
patent: 5182107 (1993-01-01), Friden
patent: 5527527 (1996-06-01), Friden
Hoogenboom, H.R. et al., "Cloning and Expression of a Chimeric Antibody Directed Against the Human Transferrin Receptor," J. Immunology, 144 (8): 3211-3217, (Apr. 15, 1990).
Trowbridge, I.S. et al., "Anti-transferrin Receptor Monoclonal Antibody and Toxin-antibody Conjugates Affect Growth of Human Tumour Cells," Nature, 294 : 171-173 (Nov. 1981).
Domingo, D.L. et al., "Transferrin Receptor as a Target for Antibody-drug Conjugates," Methods in Enzymology, 112: 238-247 (1985).
Zovickian, J. et al., "Potent and Specific Killing of Human Malignant Brain Tumor Cells by an Anti-Transferrin Receptor Antibody-Ricin Immunotoxin," J. Neurosurg., 66 : 850-861 (1987).
Jeffries, W.A. et al., "Transferrin Receptor on Endothelium of Brain Capillaries," Nature, 312 : 162-163 (nov. 8, 1984).
Raso, V. et al., "Monensin is Obligatory for the Cytotoxic Action of a Disulfide Linked Methotrexate-Anti-Transferrin Receptor Conjugate," Biochem. Biophy. Res. Comm., 150 (1): 104-110 (Jan. 15, 1988).
Alkan, S.S. et al., "Antiviral and Antiproliferative Effects of Interferons Delivered via Monoclonal Antibodies," J. Interferon Res., 4 (3): 355-363 (1984).
Capon, D.J. et al., "Designing CD4 Immunoadhesins for AIDS Therapy," Nature, 337 : 525-531 (Feb. 9, 1989).
Pietersz, G.A. et al., "Novel Synthesis and in Vitro Characterization of Disulfide-Linked Ricin-Monoclonal Antibody Conjugates Devoid of Galactose Binding Activity," Cancer Res., 48 : 4469-4476 (Aug. 15, 1988).
Pietersz, G.A. et al., "The Use of Monoclonal Antibody Conjugates for the Diagnosis and Treatment of Cancer," Immunol. and Cell. Biol., 65 (pt. 2): 111-125 (1987).
Gascoigne, N.R.J. et al., "Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein," Proc. Nat'l Acad. Sci. USA84 : 2936-2940 (May 1987).
Baldwin, R.W. et al., "Monoclonal Antibodies for Radioimmunodetection of Tumours and for Targeting," Bull. Cancer (Paris) 70(2): 132-136 (1983).
Bryn, R.A. et al., "Biological Properties of a CD4 Immunoadhesin," Nature, 344 : 667-670 (Apr. 12, 1990).
Dautry-Varsat, A. et al., "pH and the Recycling of Transferrin During Receptor Mediated Endocytosis," Proc. Nat'l. Acad. Sci. USA80 : 2258-2262 (Apr. 1983).
Pardridge, W.M., "Receptor-Mediated Peptide Transport through the Blood-Brain Barrier," Endocrine Reviews, 7 (3): 314-330.
Friden, P.M. et al., "Anti-Transferrin Receptor Antibody and Antibody-Drug Conjugates Cross the Blood-Brain Barrier," Proc. Nat'l Acad. Sci. USA, 88 (11): 4771-4775 (Jun. 1, 1991).
Huston, J.M. et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli," Proc. Natl. Acad. Sci. USA 85: 5879-5883 (Aug. 1988).
Riechmann, L. et al., "Reshaping Human Antibodies for Therapy," Nature 332 (Issue No. 6162): 323-327 (Mar. 1988).
Morrison, S.L. et al., "Chimeric Human Antibody Molecules:Mouse Antigen-Binding Domains with Human ConstantRegion Domains," Proc. Natl. acad. Sci. USA81 : 6851-6855 (Nov. 1984).
Boulianne, G.L. et al. "Production of Functional Chimeric Mouse/Human Antibody," Nature 312:643-646 (Dec. 13, 1984).
Jeffries, W.A. et al., "Analysis of Lymphopoietic Stem Cells with a Monoclonal Antibody to the Rat Transferrin Receptor," Immunology 54: 333-341 (1985).
Roitt, I.M., "Essential Immunology," Blackwell Scientific Publications pp. 65-68 & 74 (1991).
Bach, J.F. et al., "Safety and Efficacy of Therapeutic Monoclonal Antibodies in Clinical Therapy," Immunology Today 14(9): 421-425 (1993).
Gregoriadis, G. and A.T. Florence, "Recent Advances in Drug Targeting," Trends in Biotech 11: 440-42 (Nov. 1993).
Thorpe, R., "Monoclonal Antibodies: Clinical andRegulatory Issues," Trends in Biotech 11: 40-42 (Feb. 1993).
Hoogenboom, H.R. et al., "Construction and Expression of Antibody-Tumor Necrosis Factor Fusion Proteins," Molecular Immunology, 28(9) : 1027-1037 (Sep. 1991).
Shen, W.-C. et al., "Cis-Aconityl Spacer between Daunomycin and Macromolecular Carriers: A Model of pH-Sensitive Linkage Releasing Drug from a Lysosomotropic Conjugate," Biochem. & Biophy. Res. Comm. 102(3): 1048-1054, (Oct. 15, 1981).
Fishman, J.B. et al., "Receptor-Mediated Transcytosis of Transferrin Across the Blood-Brain Barrier," J. Neur. Res., 18: 299-304 (1987).
Pardridge, W.M. et al., "Selective Transport of an Anti-Transferrin Receptor Antibody through the Blood-Brain Barrier in Vivo," J. Pharmacol. and Exp. Therapeutics, 259(1): 66-70 (1991).
Sutherland, R. et al., "Ubiquitous Cell-Surface Glycoprotein on Tumor Cells is Proliferation-Associated Receptor for Transferrin," Proc. Nat'l Acad. Sci. USA, 78(7): 4515-4519 (Jul. 1981).
Batra, J.K. et al., "Antitumor Activity in Mice of an Immunotoxin made with Anti-Transferrin Receptor and a Recombinant Form of Pseudomonas Exotoxin," Proc. Nat'l Acad. Sci. USA, 86: 8545-8549 (Nov. 1989).
Batra, J.K. et al., "Single-Chain Immunotoxins Directed at the Human Transferrin Receptor Containing Pseudomonas Exotoxin A or Diphtheria Toxin: Anti-TFR(Fv)-PE40 and DT388-Anti-TFR(Fv)," Mol. and Cell. Biol. 11(4): 2200-2205 (Apr. 1991).
Friden, P.M. et al., "Blood-Brain Barrier Penetration and in Vivo Activity of an NGF Conjugate," Science 259: 373-377 (Jan. 15, 1993).
Cazzola, M. et al., "Cytotoxic Activity of an Anti-Transferrin Receptor Immunotoxin on Normal and Leukemic Human Hematopoietic Progenitors," Cancer Res. 51: 536-541 (Jan. 15, 1991).
Bjorn, M. et al., "Immunotoxins to the Murine Transferrin Receptor: Intracavitary Therapy of Mice Bearing Syngeneic Paritoneal Tumors," Cancer Res. 47: 6639-6645 (Dec. 15, 1987).
Smyth, M.J. et al., "The Mode of Action of Methotrexate-Monoclonal Antibody Conjugates," Immun. and Cell Biol. 65(Pt. 2): 189-200 (1987).
Griffin, T.W. et al., "In Vitro Cytotoxicity of Recombinant Ricin A Chain-Antitransferrin Receptor Immunotoxin Against Human Adenocarcinomas of the Colon and Pancreas," J. of Biological Response Modifiers 7(6): 559-567 (1988).
Pirker, R. et al., "Anti-Transferrin Receptor Antibody Linked to Pseudomonas Exotoxin as a Model Immunotoxin in Human Ovarian Carcinoma Cell Lines," Cancer Res. 45: 751-757 (Feb. 1985).
Morrison, S.L. et al., "Genetically Engineered Antibody Molecules: New Tools for Cancer Therapy," Cancer Investigation 6(2): 185-192 (1988).
Alkermes, Inc.
Burke Julie
LandOfFree
Transferrin receptor specific antibody-neuropharmaceutical or di does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transferrin receptor specific antibody-neuropharmaceutical or di, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transferrin receptor specific antibody-neuropharmaceutical or di will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-561148